2-Substituted quinoline compounds and their uses
AssigneeRigel Pharmaceuticals, Inc.
InventorsHui Li, Rajinder Singh
Life of this patent
Estimating the term…
Abstract
The present disclosure provides 2-substituted-quinoline compounds that inhibit the IgE receptor signaling cascade that leads to the release of chemical mediators, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and/or prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE receptor signaling cascade.
Claims34
A compound comprising a quinolinyl moiety, a five-membered saturated, unsaturated or aromatic heterocyclic moiety containing at least two nitrogen ring atoms and an —NH— bridge linking a ring carbon of the heterocyclic moiety to the 2-position of the quinolinyl moiety, wherein the quinolinyl moiety is substituted at one or more of the 4-, 6- and/or 8-positions and the heterocyclic moiety is optionally substituted at one or more available ring carbon atoms.
The compound of claim 18 in which R9 is bromo and R10 is phenyl.
Dependencies are inferred from the claim text.